Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in <scp>DAYBREAK</scp> Trial Participants

Most participants did not relapse within 90 days following ozanimod discontinuation. Post-treatment relapse cases suggestive of a rebound effect were not observed.

Authors

Institutions

Publication Details

Journal
Annals of Clinical and Translational Neurology
Published
2026-03-27
DOI
https://doi.org/10.1002/acn3.70366
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Bruce Cree, Krzysztof Selmaj, James K. Sheffield, Erik DeBoer et al.
Annals of Clinical and Translational Neurology
Multiple Sclerosis Research Studies
article

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Bruce Cree, Krzysztof Selmaj, James K. Sheffield, Erik DeBoer, G. Comi, Eva Havrdová, Jon Riolo, Andrew Thorpe, Hetal Desai, Ralf Gold, Chun‐Yen Cheng, Regina Berkovich, Jeffrey A. Cohen
article en

Abstract

Most participants did not relapse within 90 days following ozanimod discontinuation. Post-treatment relapse cases suggestive of a rebound effect were not observed.

Annals of Clinical and Translational Neurology
Cleveland Clinic (US), Vita-Salute San Raffaele University (IT), University of California, San Francisco (US), Charles University (CZ), Bristol-Myers Squibb (United States) (US), Medical University of Lodz (PL), Neurology Center of Southern California (US), St. Josef-Hospital (DE), General University Hospital in Prague (CZ), University of Warmia and Mazury in Olsztyn (PL)
Openalex Percentile: Top 5%
Multiple Sclerosis Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in <scp>DAYBREAK</scp> Trial Participants — Bruce Cree, Krzysztof Selmaj, et al. · Annals of Clinical and Translational Neurology (2026) | TGRS Research Map | TGRS